IMPACT OF VENETOCLAX-BASED THERAPY ON T- AND NK-CELL IMMUNITY IN CHRONIC LYMPHOCYTIC LEUKEMIA (SIE 2026) - Oct 6, 2026 - Abstract #DP025; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Within the γδ T-cell compartment, both Vδ1 and Vγ9Vδ2 subsets significantly decreased, although Vγ9Vδ2 T cells exhibited enhanced degranulation capacity following IL2 and zoledronic acid stimulation. Functionally, NK cells exhibit- ed increased ADCC activity as early as 1 month after treat- ment initiation against a CD20+ cell line in the presence of rituximab or obinutuzumab. Overall, these findings support the notion of treatment-induced immune reprogramming that should be considered when defining optimal therapeu- tic sequencing, particularly in the context of immunothera- peutic strategies."
IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • BTLA • CD20 • CD4 • CD8 • HAVCR2 • IL2 • LAG3 • PD-1
|
|
G. Mancin1,2; V. Griggio1,2; R. Jones1,2; G. Bondielli1,2; A. Visentin3; R. Moia4; Am. Frustaci5; A. Bosi6; M. Varettoni7; F. Perutelli1,2; G. Catania8; P. Sportoletti9; L. Laurenti10; Fr. Mauro11; L. Orsucci12; L. Arcaini7,13; F. Passamonti6; M. Deodato5; G. Gaidano4; L. Trentin3; B. Bruno1,2; C. Vitale1,2; M. Coscia14,15
|